Beneficial Ownership Report - Form SC 13D

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

[Rule 13d-101]

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a)

(Amendment No. )*

Singular Genomics Systems, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

82933R308

(CUSIP Number)

David Clark

Elliot Press

Deerfield Management Company, L.P.

345 Park Avenue South, 12 Floor

New York, New York 10010

(212) 551-1600

With a copy to:

Jonathan D. Weiner, Esq.

Mark D. Wood, Esq.

Katten Muchin Rosenman LLP

50 Rockefeller Plaza

New York, New York 10020

(212) 940-8800

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

September 5, 2024

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☒.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

(Continued on following pages)
(Page 1 of 12 Pages)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 82933R308

Page 2 of 12 Pages

1	NAMES OF REPORTING PERSONS Deerfield Mgmt IV, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*	(a) ☐ (b) ☒
3	SEC USE ONLY
AF	SOURCE OF FUNDS AF
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)	☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER 0
8	SHARED VOTING POWER 249,495 (1)
9	SOLE DISPOSITIVE POWER 0
10	SHARED DISPOSITIVE POWER 249,495 (1)
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 249,495 (1)
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*	☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 6.66%
14	TYPE OF REPORTING PERSON PN

(1) Comprised of (i) 166,162 shares of common stock and (ii) 83,333 shares of common stock issuable upon conversion of 2,500 shares of Series A Common Stock Equivalent Convertible Preferred Stock, in each case, held by Deerfield Private Design Fund IV, L.P. The terms of the Series A Common Stock Equivalent Convertible Preferred Stock restrict the conversion of such shares to the extent that, upon such conversion, the number of shares of common stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 4.9% of the total number of shares of common stock then outstanding (the "Ownership Cap"). Accordingly, notwithstanding the number of shares reported, the reporting person disclaims beneficial ownership of the shares of common stock issuable upon conversion of Series A Common Stock Equivalent Convertible Preferred Stock to the extent that upon such conversion the number of shares beneficially owned by all reporting persons hereunder, in the aggregate, would exceed the Ownership Cap.

SCHEDULE 13D

CUSIP No. 82933R308

Page 3 of 12 Pages

1	NAMES OF REPORTING PERSONS Deerfield Private Design Fund IV, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*	(a) ☐ (b) ☒
3	SEC USE ONLY
4	SOURCE OF FUNDS WC
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)	☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER 0
8	SHARED VOTING POWER 249,495 (2)
9	SOLE DISPOSITIVE POWER 0
10	SHARED DISPOSITIVE POWER 249,495 (2)
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 249,495 (2)
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*	☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 6.66%
14	TYPE OF REPORTING PERSON PN

(2) Comprised of (i) 166,162 shares of common stock and (ii) 83,333 shares of common stock issuable upon conversion of 2,500 shares of Series A Common Stock Equivalent Convertible Preferred Stock. The terms of the Series A Common Stock Equivalent Convertible Preferred Stock restrict the conversion of such shares to the extent that, upon such conversion, the number of shares of common stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 4.9% of the total number of shares of common stock then outstanding (the "Ownership Cap"). Accordingly, notwithstanding the number of shares reported, the reporting person disclaims beneficial ownership of the shares of common stock issuable upon conversion of Series A Common Stock Equivalent Convertible Preferred Stock to the extent that upon such conversion the number of shares beneficially owned by all reporting persons hereunder, in the aggregate, would exceed the Ownership Cap.

SCHEDULE 13D

CUSIP No. 82933R308

Page 4 of 12 Pages

1	NAMES OF REPORTING PERSONS Deerfield Management Company, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*	(a) ☐ (b) ☒
3	SEC USE ONLY
4	SOURCE OF FUNDS AF
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)	☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER 0
8	SHARED VOTING POWER 249,495 (3)
9	SOLE DISPOSITIVE POWER 0
10	SHARED DISPOSITIVE POWER 249,495 (3)
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 249,495 (3)
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*	☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 6.66%
14	TYPE OF REPORTING PERSON PN

(3) Comprised of (i) 166,162 shares of common stock and (ii) 83,333 shares of common stock issuable upon conversion of 2,500 shares of Series A Common Stock Equivalent Convertible Preferred Stock, in each case, held by Deerfield Private Design Fund IV, L.P. The terms of the Series A Common Stock Equivalent Convertible Preferred Stock restrict the conversion of such shares to the extent that, upon such conversion, the number of shares of common stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 4.9% of the total number of shares of common stock then outstanding (the "Ownership Cap"). Accordingly, notwithstanding the number of shares reported, the reporting person disclaims beneficial ownership of the shares of common stock issuable upon conversion of Series A Common Stock Equivalent Convertible Preferred Stock to the extent that upon such conversion the number of shares beneficially owned by all reporting persons hereunder, in the aggregate, would exceed the Ownership Cap.

SCHEDULE 13D

CUSIP No. 82933R308

Page 5 of 12 Pages

1	NAMES OF REPORTING PERSONS James E. Flynn
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*	(a) ☐ (b) ☒
3	SEC USE ONLY
4	SOURCE OF FUNDS AF
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)	☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION United States of America
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER 0
8	SHARED VOTING POWER 249,495 (4)
9	SOLE DISPOSITIVE POWER 0
10	SHARED DISPOSITIVE POWER 249,495 (4)
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 249,495 (4)
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*	☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 6.66%
14	TYPE OF REPORTING PERSON IN

(4) Comprised of (i) 166,162 shares of common stock and (ii) 83,333 shares of common stock issuable upon conversion of 2,500 shares of Series A Common Stock Equivalent Convertible Preferred Stock, in each case, held by Deerfield Private Design Fund IV, L.P. The terms of the Series A Common Stock Equivalent Convertible Preferred Stock restrict the conversion of such shares to the extent that, upon such conversion, the number of shares of common stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 4.9% of the total number of shares of common stock then outstanding (the "Ownership Cap"). Accordingly, notwithstanding the number of shares reported, the reporting person disclaims beneficial ownership of the shares of common stock issuable upon conversion of Series A Common Stock Equivalent Convertible Preferred Stock to the extent that upon such conversion the number of shares beneficially owned by all reporting persons hereunder, in the aggregate, would exceed the Ownership Cap.

CUSIP No. 82933R308

6 of 12 Pages

This Schedule 13D is filed by (i) Deerfield Mgmt IV, L.P. ("Deerfield Mgmt IV"), (ii) Deerfield Private Design Fund IV, L.P. ("Deerfield Private Design Fund IV"), (iii) Deerfield Management Company, L.P. ("Deerfield Management"), and (iv) James E. Flynn, a natural person ("Flynn" and collectively with Deerfield Mgmt IV, Deerfield Private Design Fund IV, Deerfield Management and Flynn, the "Reporting Persons"), with respect to the Common Stock (as defined in Item 1) of Singular Genomics Systems, Inc.

Item 1. Security and Issuer.

This Statement on Schedule 13D relates to the shares of common stock, par value $0.0001 per share (the "Common Stock"), of Singular Genomics Systems, Inc., a Delaware corporation (the "Company"). The address of the Company's principal executive offices is 3010 Science Park Road, San Diego, California, 92121.

Item 2. Identity and Background.

(a)	This Statement is filed as a joint statement pursuant to Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934 (the "Exchange Act") by the Reporting Persons.

(b)	The address of the principal business and/or principal office of each Reporting Person is 345 Park Avenue South, 12th Floor, New York, New York 10010.

(c)

Flynn is the managing member of the general partner of each of Deerfield Mgmt IV and Deerfield Management. Deerfield Mgmt IV is the general partner of Deerfield Private Design Fund IV, and Deerfield Management is the investment manager of Deerfield Private Design Fund IV. Deerfield Private Design Fund IV purchases, holds and sells securities and other investment products. Schedule A hereto sets forth information regarding persons referred in Instruction C to Schedule 13D.

(d)	During the last five years, none of the Reporting Persons, nor, to the best of each of the Reporting Person's knowledge, any of the persons listed on Schedule A attached hereto, has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

During the last five years, none of the Reporting Persons, nor, to the best of each of the Reporting Person's knowledge, any of the persons listed on Schedule A attached hereto, has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(e)	Each of Deerfield Mgmt IV, Deerfield Private Design Fund IV and Deerfield Management is organized under the laws of the State of Delaware. Flynn is a citizen of the United States of America.

The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is attached hereto as Exhibit A.

CUSIP No. 82933R308

7 of 12 Pages

Item 3. Source and Amount of Funds or Other Consideration.

Prior to the Company's initial public offering (the "IPO") in May 2021, Deerfield Private Design Fund IV participated in debt and equity financings involving the Company.

In June 2019, Deerfield Private Design Fund IV acquired 6,457,723 shares (the "Series B Conversion Shares") of the Company's Series B convertible preferred Stock ("Series B Preferred Stock") from the Company for an aggregate purchase price of approximately $15,000,000. Upon the closing of the Issuer's IPO, each such share of Series B Preferred Stock automatically converted into one share of Common Stock (without giving effect to the June 2024 Reverse Stock Split (as defined below)).

In February 2021, Deerfield Private Design Fund IV purchased $10,000,000 aggregate principal amount of the Company's convertible notes (the "2021 Convertible Notes") from the Company for $10,000,000. Upon the closing of the IPO, the 2021 Convertible Notes, including accrued interest thereon, converted into an aggregate of 577,148 shares (the "2021 Note Conversion Shares") of Common Stock (on an unadjusted basis, without giving effect to the June 2024 Reverse Stock Split) at a conversion price equal to $17.60 per share.

In connection with the IPO, Deerfield Private Design Fund IV acquired 450,000 shares (the "IPO Shares") of Common Stock (on an unadjusted basis, without giving effect to the June 2024 Reverse Stock Split), for $22.00 per share. The aggregate purchase price paid by Deerfield Private Design Fund IV and Deerfield Partners for such shares was $9,900,000.

On January 25, 2022, Deerfield Private Design Fund IV and the Company entered into an Exchange Agreement, pursuant to which Deerfield Private Design Fund IV exchanged an aggregate of 2,500,000 shares of Common Stock (on an unadjusted basis, without giving effect to the June 2024 Reverse Stock Split) for 2,500 shares of Series A Common Stock Equivalent Convertible Preferred Stock ("Series A Preferred Stock"). Each share of Series A Preferred Stock is convertible into 33.33 shares of Common Stock (on an adjusted basis, giving effect to the June 2024 Reverse Stock Split), subject to further adjustment as provided in the Certificate of Designation of Preferences, Rights and Limitations of Series A Preferred Stock (the "Series A Certificate of Designation").

On June 25, 2024, the Company effected a 1-for-30 reverse stock split of its Common Stock (the "June 2024 Reverse Stock Split"), which became effective at 12:01 a.m. Eastern Time on June 26, 2024. As a result of the June 2024 Reverse Stock Split, the Series B Conversion Shares, 2021 Note Conversion Shares and IPO Shares were converted into an aggregate of 166,162 shares of Common Stock. As a result of the June 2024 Reverse Stock Split, the conversion rate applicable to the Series A Preferred Stock was proportionately adjusted pursuant to the Series A Certificate of Designation.

Prior to the IPO, Andrew ElBardissi, an employee of Deerfield Management, served as a director of the Company and, on March 19, 2021, the Company granted an option to purchase shares of Common Stock to Andrew ElBardissi for his service as a director of the Company. As of the date of this report, such option is exercisable in respect of 1,000 shares of Common Stock (on an adjusted basis, giving effect to the June 2024 Reverse Stock Split). Such option is held for the benefit, and subject to the direction, of Deerfield Management. Mr. ElBardissi resigned as a director of the Company immediately prior to the pricing of the IPO.

CUSIP No. 82933R308

8 of 12 Pages

Except as otherwise indicated herein, Deerfield Private Design Fund IV utilized its working capital to purchase the shares of Common Stock reported herein. Shares of Common Stock beneficially owned by the Reporting Persons are or may be held from time to time by Deerfield Private Design Fund IV in margin accounts established with its brokers or banks, and a portion of the purchase price for the Common Stock may have been obtained through margin borrowing. Common Stock positions held in margin accounts may be pledged as collateral security for the repayment of debit balances in the margin accounts.

Item 4. Purpose of Transaction.

The information set forth in Item 3 and Item 6 is incorporated herein by reference.

On September 5, 2024, Deerfield Private Design Fund IV, Deerfield Mgmt IV and Deerfield Management (collectively, "Deerfield") submitted a non-binding proposal (the "September 2024 Proposal") to the special committee of independent directors of the Company (the "Special Committee"). The September 2024 Proposal relates to a proposed acquisition through a special purpose vehicle to be established by Deerfield of all of the outstanding shares of Common Stock not already owned by Deerfield or any other stockholders or members of management that Deerfield invites to "rollover" their current equity shares for a purchase price of $10.00 per share, in cash (the "Proposed Transaction"). The September 2024 Proposal contemplates (i) inviting other major stockholders to rollover their shares of Common Stock into the combined company and support the Proposed Transaction, and (ii) that existing management holders of shares of Common Stock (including any members of the Special Committee) would have a desire to participate in the rollover. The September 2024 Proposal indicates that Deerfield expects holders of over 50% of the outstanding shares of Common Stock, in total, would rollover into the combined company. It also indicates that Deerfield will not move forward with the Proposed Transaction (or any similar transaction) unless it is recommended to the board of directors of the Company (the "Board") by the Special Committee and thereafter approved by the Board, and that prior to moving forward Deerfield would expect to enter into an exclusivity agreement with the Company.

The September 2024 Proposal contemplates that the Proposed Transaction would be fully financed by committed equity financing and not be subject to any financing condition.

Any definitive agreement entered into in connection with the Proposed Transaction would be subject to customary closing conditions, including approval by the Special Committee, any required stockholder approvals and approval by any applicable regulatory authorities. No assurance can be given that any definitive agreement will be entered into, that the Proposed Transaction will be consummated, or that the Proposed Transaction will be consummated on the terms set forth in the September 2024 Proposal. Deerfield reserves the right to modify or withdraw the Proposal at any time and no binding obligation on the part of any of the Reporting Persons or any of their affiliates will arise with respect to the filing of this Statement.

CUSIP No. 82933R308

9 of 12 Pages

In furtherance of the September 2024 Proposal, the Reporting Persons and their affiliates expect to engage in communications and discussions with the Company, members of the Special Committee and, with the permission of the Special Committee, management of the Company. Among other things, the Reporting Persons expect to respond to inquiries from, and negotiate the terms of the September 2024 Proposal with, the Special Committee and its representatives. The Reporting Persons also expect to engage in communications and discussions with other current or prospective stockholders of the Company, potential co-investors and financing sources (including current or potential investors in funds managed by Deerfield), investment and financing professionals, industry analysts and other knowledgeable industry or market observers and participants, and other interested parties regarding the Transaction and/or the matters set forth in the September 2024 Proposal, and may exchange information with such persons pursuant to appropriate confidentiality or similar agreements.

The Reporting Persons do not currently intend to or provide updated or additional disclosures regarding the September 2024 Proposal or the Proposed Transaction unless and until a definitive agreement has been reached, unless disclosure is otherwise required under applicable U.S. securities laws.

The September 2024 Proposal may result in one or more of the transactions, events or actions specified in clauses (a) through (j) of Item 4 of Schedule 13D, including, without limitation, an acquisition of additional securities of the Issuer, an extraordinary corporate transaction (such as a merger) involving the Company, delisting of the Common Stock of from the Nasdaq Capital Market and other material changes in the Company's business or corporate structure.

Reference to the September 2024 Proposal in this Amendment No. 1 is qualified in its entirety by reference to the copy of the September 2024 Proposal, which is attached hereto as Exhibit 2, and incorporated herein by reference in its entirety.

Except for the foregoing, none of the Reporting Persons has any plans or proposals which relate to, or would result in, any of the matters referred to in paragraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons may, at any time and from time to time, formulate other purposes, plans or proposals regarding the Issuer, or any other actions that could involve one or more of the types of transactions or have one or more of the results described in paragraphs (a) through (j) of Item 4 of Schedule 13D.

Item 5. Interest in Securities of the Issuer.

(a)

(1)	Deerfield Mgmt IV
		Number of shares:	249,495 (comprised of shares, and shares underlying Series A Preferred Stock, held by Deerfield Private Design Fund IV)
		Percentage of shares:	6.66%
	(2)	Deerfield Management
		Number of shares:	249,495 (comprised of shares, and shares underlying Series A Preferred Stock, held by Deerfield Private Design Fund IV)
		Percentage of shares:	6.66%
	(3)	Deerfield Private Design Fund IV
		Number of shares:	249,495 (comprised of shares, and shares underlying Series A Preferred Stock, held directly)
		Percentage of shares:	6.66%

CUSIP No. 82933R308

10 of 12 Pages

	(4)	Flynn
		Number of shares:	249,495 (comprised of shares, and shares underlying Series A Preferred Stock, held by Deerfield Private Design Fund IV)
		Percentage of shares:	6.66%
(b)
	(1)	Deerfield Mgmt IV
		Sole power to vote or direct the vote: 0
		Shared power to vote or direct the vote: 249,495
		Sole power to dispose or to direct the disposition: 0
		Shared power to dispose or direct the disposition: 249,495
	(2)	Deerfield Management
		Sole power to vote or direct the vote: 0
		Shared power to vote or direct the vote: 249,495
		Sole power to dispose or to direct the disposition: 0
		Shared power to dispose or direct the disposition: 249,495
	(3)	Deerfield Private Design Fund IV
		Sole power to vote or direct the vote: 0
		Shared power to vote or direct the vote: 249,495
		Sole power to dispose or to direct the disposition: 0
		Shared power to dispose or direct the disposition: 249,495
	(4)	Flynn
		Sole power to vote or direct the vote: 0
		Shared power to vote or direct the vote: 249,495
		Sole power to dispose or to direct the disposition: 0
		Shared power to dispose or direct the disposition: 249,495

Flynn is the sole member of the general partner of each of Deerfield Mgmt IV and Deerfield Management. Deerfield Mgmt IV is the general partner, and Deerfield Management is the investment manager, of Deerfield Private Design Fund IV.

(c) Except as set forth in Items 3 and 4 of this Schedule 13D, the Reporting Persons have not engaged in any transactions in the Company's securities during the past 60 days.

CUSIP No. 82933R308

11 of 12 Pages

(d) As of the date of this Schedule 13D, no person other than the Reporting Persons is known to the Reporting Persons to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock covered by this Schedule 13D.

(e) Not applicable.

Item 6.

Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

In January, February and March 2022, Deerfield Private Design Fund IV entered into a cash-settled swaps with UBS AG ("UBS") which represent economic exposure comparable to a notional interest in 73,640 shares of Common Stock (representing 2.95% of the issued and outstanding Common Stock), in addition to the shares of Common Stock beneficially owned by the Reporting Persons. Under the terms of each of the swaps, (i) Deerfield Private Design Fund IV will be obligated to pay to UBS any negative price performance of the specified notional number of shares of Common Stock subject to the swap as of the expiration date of such swap, plus interest at rates set forth in the applicable contracts, and (ii) UBS will be obligated to pay Deerfield Private Design Fund IV any positive price performance of the specified notional number of shares of Common Stock subject to the swap as of the expiration date of the swap, plus interest at rates set forth in the applicable contracts. All balances will be settled in cash. The swaps do not give Deerfield Private Design Fund IV or any other Reporting Person direct or indirect voting, investment or dispositive control over any securities of the Company and do not require the counterparty thereto to acquire, hold, vote or dispose of any securities of the Company. Accordingly, the Reporting Persons do not beneficially own any shares of Common Stock that may be referenced in the swap contracts or in any Common Stock or other securities or financial instruments that may be held from time to time by the counterparty to the contracts. The swaps expire on February 1, 2027.

Item 7.

Material to be Filed as Exhibits.

Exhibit 1

Joint Filing Agreement dated as of March 5, 2018 by and among the Reporting Persons.*

Exhibit 2

Power of Attorney previously filed as Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P., Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P., Deerfield Management Company, L.P. and James E. Flynn.

Exhibit 3

Non-binding Indication of Interest, submitted September 5, 2024*

* Filed herewith.

CUSIP No. 82933R308

12 of 12 Pages

SIGNATURE

After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: September 12, 2024

	DEERFIELD MGMT IV, L.P.
	By: J.E. Flynn Capital IV, LLC, General Partner
	By:	/s/ Jonathan Isler
	Name:	Jonathan Isler
	Title:	Attorney-in-Fact
	DEERFIELD PRIVATE DESIGN FUND IV, L.P.
	By: Deerfield Mgmt IV, L.P., General Partner
	By: J.E. Flynn Capital IV, LLC, General Partner
	By:	/s/ Jonathan Isler
	Name:	Jonathan Isler
	Title:	Attorney-in-Fact
	DEERFIELD MANAGEMENT COMPANY, L.P.
	By: Flynn Management LLC, General Partner
	By:	/s/ Jonathan Isler
	Name:	Jonathan Isler
	Title:	Attorney-in-Fact
	JAMES E. FLYNN
	/s/ Jonathan Isler
	Jonathan Isler, Attorney-in-Fact

Schedule A

General Partner of Deerfield Mgmt IV, L.P.

The general partner of Deerfield Mgmt IV is J.E. Flynn Capital IV, LLC. The address of the principal business and/or principal office of Deerfield Mgmt IV and J.E. Flynn Capital IV, LLC is 345 Park Avenue South, 12th Floor, New York, New York 10010.

General Partner of Deerfield Private Design Fund IV, L.P.

The general partner of Deerfield Private Design Fund IV is Deerfield Mgmt IV. The address of the principal business and/or principal office of Deerfield Mgmt IV and Deerfield Private Design Fund IV is 345 Park Avenue South, 12th Floor, New York, New York 10010.

General Partner of Deerfield Management Company, L.P.

The general partner of Deerfield Management is Flynn Management LLC. The address of the principal business and/or principal office of Deerfield Management and Flynn Management LLC is 345 Park Avenue South, 12th Floor, New York, New York 10010.

Exhibit Index

Exhibit

Number Description

Exhibit 1

Joint Filing Agreement dated as of March 5, 2018 by and among the Reporting Persons.*

Exhibit 2

Power of Attorney previously filed as Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P., Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P., Deerfield Management Company, L.P. and James E. Flynn.

Exhibit 3

Non-binding Indication of Interest, submitted September 5, 2024*

* Filed herewith.

Public link

Please use the above public link if you want to share this noodl on another website.